Going forward, immediate resistance is seen around 11,350-11,375 followed by 11,450. On the other hand, Nifty now trades overbought and if it retreats, we expect the level of 10,260, followed by 11,180, as the support levels. Stocks in news: NHPC, Dr Reddy’s Laboratories, Mahindra and Mahindra, HDFC Bank and Texmaco Rail and Engineering.

The SGX Nifty, which was trading down by 14 points at 11,329, indicated that domestic bourses may open with modest losses at the opening bell. Among Nifty 50 companies, Power Grid, Tata Motors, UPL and Vedanta numbers are slated today. On the macro front, the government will release infrastructure output data for the month of June.  

The stocks that are likely to witness significant movement on the bourses on July 31 are HDFC Ltd, Tech Mahindra, Solar Industries, Thomas Cook and Cadila Healthcare.

Its EBITDA for the quarter rose by 57.1 per cent YoY to Rs. 13.32 crore, with a corresponding margin expansion of 316 bps. The EBITDA margin for the quarter stood at 16.5 per cent.

S&P BSE 200 index opened with a gap-up on Monday, followed by a gap filling but ultimately bounced back to close in green at its peak levels. The index had given a multiple resistance breakout near 4,750 and since then has hit higher high with just one breather in between. 5 BSE 200 stocks hit 52-week high on Monday.

Your behaviour shapes your style of investment. Read on to know more about emotional traps and how to override them.

Godrej Consumer Products reported steady results in Q1FY19. The top line grew in single digits while bottom-line grew strongly.

In terms of volume, tractor volume grew by 39.5 per cent at 24,494 units and construction equipment volume grew by 51.8 per cent to 1,345 units.

Jio has continued its strong subscriber growth trend with net addition during the quarter of 28.7 million (as against 26.5 million in the previous quarter). This is the highest net addition in any quarter since the launch of commercial services.

The company stated that clinical research business will hit top-line from the last quarter of the ongoing financial year. The company is expecting to add a revenue of Rs. 250 crores in the fifth year through clinical research services.